Our model indicates that radiation + anti‐PD‐L1 combination therapy is only effective in patients with pre‐existing CD8 T cells in the tumor microenvironment and that anti‐PD‐L1 should be administered early, in conjunction with RT for maximal anti‐tumor responses. This evidence concerns the gene CD8A and neoplasm.